source
- Opinion: $2 million gene therapy cures require a financing model“We do not lack cures. We lack the infrastructure to pay for and deliver them,” writes William Padula.STAT · 1mo ago↗ source
- STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADAYou're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.STAT · 1mo ago↗ source
- #ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effectsBoehringer Ingelheim’s obesity asset survodutide, which it licensed from Zealand Pharma, has shown high rates of discontinuations in its Phase 3 obesity study. In April, data from the SYNCHRONIZE-1…Endpoints · 1mo ago↗ source